Proteomics approaches utilizing cerebrospinal fl uid (CSF) to investigate the pathogenesis of neurological diseases are rapidly growing. [24] [25] [26] [27] [28] However, limited data exist on the use of proteomics in human cervical spondylotic myelopathy, or its canine counterpart, CSM. 29 , 30 Our objective was to compare the CSF proteome of clinically normal (control) dogs and dogs with osseous-associated CSM with identify CSF proteins that could enhance our understanding of the disease pathogenesis. We hypothesized that the CSF proteome of CSM-affected dogs would differ signifi cantly from that of control dogs. When compared with rodent models of human cervical spondylotic myelopathy, canine CSM more closely approximates the human condition. Canine CSM is a spontaneous chronic, progressive cervical myelopathy, human size is more comparable with canines than with rodents, and CSM-affected dogs receive high-quality medical care including diagnostic evaluations and treatments similar to those of people with cervical spondylotic myelopathy. The similarities between canine CSM and human cervical spondylotic myelopathy suggest that results from this study could also be relevant for the human condition.
MATERIALS AND METHODS

Collection and Storage of CSF
The investigation was conducted in accordance with the guidelines and with approval of the institution's Clinical Research Advisory Committee and the Institutional Animal Care and Use Committee. Two groups of client-owned Great Danes were prospectively enrolled between April 2011 and October 2012. Written owner's consent was obtained prior to enrollment. The fi rst group included 15 dogs defi ned as clinically normal based on a normal neurological examination and no history of neurological disease. The second group included 15 dogs with clinical signs and neurological examination fi ndings consistent with CSM and confi rmation via magnetic resonance imaging. Whether or not patients were being administered corticosteroids at the time of enrollment was recorded.
Cerebellomedullary cistern CSF samples (1-2 mL) were collected under general anesthesia into sterile tubes without anticoagulant. The CSF from each dog was immediately centrifuged at 3000 revolutions per minute for 8 minutes to remove cellular materials. The supernatants were collected and stored at − 80 ° C until analyzed.
Sample Preparation, Labeling, and 2-Dimensional (2-D) Electrophoresis Separation
Proteins were extracted from CSF samples using a 2-D cleanup kit (GE, 80-6484-51) , resuspended in 100 μ L of lysis buffer (30 M Tris pH 8.5, 7 M Urea, 2 M Thiourea, 4% CHAPS [3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate]) and quantitated by Bradford assay using BSA as a standard. Cydye labeling, isoelectric focusing, and gel electrophoresis of 2-D-cleaned CSF samples were performed according to standard DIGE (difference gel electrophoresis) protocols. 31 Labeled samples were combined (1 Cy3, 1 Cy5, and 25 μ g of Cy2 sample/gel) and diluted 2 × with rehydration buffer (7 M Urea, 2 M thiourea, 2% CHAPS, 1% pH 3-10 immobilized pH gradient [IPG] buffer [GE Healthcare, Pataskala, OH], 50 mM dithiotreitol, and 1% saturated bromophenol blue solution to a fi nal volume of 450 μ L and then isoelectric focused on an IPGphor II [GE Healthcare] instrument using standard isoelectric focusing protocols for pH 3-10 strips [GE Healthcare]). Finally, pH strips were reduced and alkylated, placed in 20 × 24 cm 12% SDS-PAGE gels, and run in a Dalt-12 electrophoresis system (GE Healthcare) at 2 watts per gel for 45 minutes, followed by 15 watts per gel until the dye front reached the bottom ( ∼ 4 hr).
Image Acquisition and DeCyder Analysis
Gels were scanned in a Typhoon 9400 variable mode scanner (GE Healthcare) using the appropriate settings for CyDye fl uorophores at 100-micron resolution. Preparative gels (for spot picking and protein identifi cation) were stained with Lava purple general protein stain (Gel Company, San Francisco, CA) according to standard protocols. Gel images were loaded into DeCyder 2-D software (GE Healthcare) and analyzed individually. Log-standardized abundance was the variable subjected to statistical analysis. A Student t test was used to detect differences between CSM-affected and control Great Danes ( P < 0.05). The following 3 comparisons were made in Decyder: (1) control versus CSM-affected dogs, (2) control versus noncorticosteroid-treated CSM-affected dogs, and (3) non-corticosteroid-treated CSM-affected versus corticosteroid-treated CSM-affected dogs. For each comparison, spots exhibiting a statistically signifi cant change of at least 1.25-fold were selected for subsequent identifi cation.
were determined by capillary-liquid chromatography tandem mass spectrometry (Cap-LC/MS/MS) using an UltiMate 3000 LC system and an LTQ mass spectrometer (both from Thermo Scientifi c) equipped with a CaptiveSpray source (Bruker Daltonics Billerica, MA) operated in positive ion mode according to standard methods in the OSU CCIC Mass Spectrometry and Proteomics Facility. 32 The MS/MS (tandem mass spectrometry) data acquired were converted into mascot generic fi les (.mgf) using MS Convert (ProteoWizard), and the resulting fi les were searched against all NCBInr other Mammalia using Mascot Daemon by Matrix Science version 2.2.1 (Boston, MA), setting the mass tolerance of the precursor ions and fragment ions at 1.8 and 0.8 Da, respectively. Considered modifi cations were oxidation, deamidation, and carbamidomethylation. Protein identifi cations were checked manually, and proteins with only a Mascot score of 100 or higher with a minimum of 2 unique bold red peptides were accepted.
RESULTS
The characteristics of the dogs enrolled are summarized in Table 1 . Analysis with DeCyder revealed 96 total spots with a statistically signifi cant average change of at least 1.25-fold in 1 of the 3 comparisons ( Tables 2-4 and Figure 1 ). Table 2 summarizes the proteins that demonstrated differential expression when comparing the CSF of control and CSM-affected dogs. Table 3 includes the proteins that were differentially expressed in the CSF of control dogs versus non-corticosteroid-treated CSM-affected dogs. Proteins exhibiting differential expression between the CSF of non-corticosteroid-treated CSMaffected and corticosteroid-treated CSM-affected dogs are shown in Table 4 . Positive values for fold change indicate greater expression in the CSF of CSM-affected dogs than that of control dogs ( Table 2 ) , non-corticosteroid-treated CSMaffected dogs than that of control dogs ( Table 3 ) , and corticosteroid-treated CSM-affected dogs than that of non-corticosteroid-treated CSM-affected dogs ( Table 4 ) . Compared with the CSF of control dogs, CSM-affected dogs demonstrated increased CSF expression of 8 proteins including vitamin D-binding protein (DBP), gelsolin, creatine kinase B-type (CK-BB), angiotensinogen, α -2-HS-glycoprotein, SPARC (secreted protein, acidic, rich in cysteine), calsyntenin-1, and complement C3, and decreased expression of pigment epithelium-derived factor (PEDF), prostaglandin-H2 D-isomerase (PGH2), apolipoprotein E (APOE), and clusterin. APOE and clusterin showed decreased expression in CSM-affected dogs when compared with control dogs ( Table 3 ) , but their expression increased in those CSM-affected dogs that were receiving corticosteroids ( Tables 2 and 4 ). Haptoglobin, transthyretin isoform 2, and cystatin C-like were upregulated in CSM-affected dogs, but their upregulation seemed to be related to corticosteroid treatment ( Tables 2 and 4 ) because this upregulation was not observed when the effect of corticosteroids was removed ( Table 3 ) . Corticosteroid treatment decreased the CSF expression of angiotensinogen, α -2-HSglycoprotein, and gelsolin in CSM-affected dogs. Table 5 classifi es the key proteins identifi ed in this study according to their main functional category.
DISCUSSION
Several proteins showed differential expression in the CSF of clinically normal and CSM-affected dogs. In addition, corticosteroid administration seemed to alter the expression of some proteins in CSM-affected dogs. DBP participates in vitamin D transport, actin scavenging, and macrophage and osteoclast activation. [33] [34] [35] This protein was upregulated in CSM-affected dogs consistent with various human neurological diseases. 27, 33, 34, 36, 37 Because DBP has limited passage through the intact blood-brain barrier, 34 , 38 elevated CSF DBP in canine CSM suggests blood-SC barrier compromise. Blood-SC barrier disruption was reported in a rodent model of human cervical spondylotic myelopathy, 3 and it may be present in CSM-affected dogs. Gelsolin was also upregulated in CSM-affected dogs. Both DBP and gelsolin act as actin regulatory proteins and actin scavengers. 27 , 34 , 39 , 40 Actin is released secondary to axonal degeneration, 34 , 39 which is a feature of canine CSM. 12 The upregulation of CSF DBP and gelsolin in CSM-affected dogs may be secondary to axonal damage and actin excess and result from an attempt to promote actin reorganization and tissue regrowth. 41 As such, these 2 proteins could be useful as indirect markers of damaged neural tissue.
CK-BB is predominantly found in neurons and astrocytes 42 , 43 and was upregulated in CSM-affected dogs. Increased CSF CK-BB has been reported in other human and animal myelopathic disorders. [44] [45] [46] High CSF CK-BB activity is associated with white matter damage and myelin degeneration, 46 which are present in the SC of CSM-affected dogs, 12 and may explain the results obtained in this study.
Angiotensinogen is a serine protease inhibitor. 47 Serine proteases promote cartilage destruction in osteoarthritis. 48 , 49 Here, greater expression of CSF angiotensinogen in CSMaffected dogs, which had marked osteoarthritic changes of their cervical vertebrae, might be a compensatory increase in an attempt to inhibit the excess of protease activity that occurs in osteoarthritis. Similarly, α -2-HS-glycoprotein (also called "fetuin-A") was upregulated in CSM-affected dogs.
Alpha-2-HS-glycoprotein regulates calcium metabolism and osteogenesis and increases during high bone turnover. [50] [51] [52] [53] The upregulation of α -2-HS-glycoprotein in canine CSM may also be secondary to the presence of osteoarthritic changes of the cervical vertebrae.
The glycoprotein SPARC (osteonectin) participates in bone development and mineralization and tissue remodeling/turnover. [54] [55] [56] Decreased expression of SPARC is associated with osteopenia, whereas elevated expression is seen in osteoarthritis. 55 , 57-59 Increased CSF SPARC in non-corticosteroidtreated CSM-affected dogs suggests that this protein may be involved in the pathogenesis of the vertebral osteoarthritic changes seen in canine CSM. Dexamethasone can decrease SPARC expression, 57 which may explain the lack of SPARC upregulation in corticosteroid-treated CSM-affected dogs. Calsyntenin-1 is a calcium-binding transmembrane protein of the neuronal postsynaptic membrane 60 , 61 and also showed increased expression in CSM-affected dogs. Altered CSF concentrations of calsyntenin-1 were present in various human neurodegenerative diseases. 25 , 62 Complement C3 is a central component of the complement cascade. 63 Human and dogs with osteoarthritis had increased expression of complement C3. 49 , 64 , 65 In this study, all CSM-affected dogs had osteoarthritic changes of their 66 and has been suggested as a targeted therapeutic approach in human osteoarthritis and traumatic SC injury. 67 , 68 Complement inhibition could also be an attractive therapeutic strategy in canine CSM.
The PEDF CSF concentration was downregulated in CSMaffected dogs, consistent with a study that showed decreased PEDF CSF concentration in human cervical spondylotic myelopathy. 29 PEDF has neuroprotective functions capable of protecting SC motor neurons from glutamate-induced injury. 69 , 70 Glutamate excitotoxicity can sustain SC neural degeneration in human cervical spondylotic myelopathy, 2 and it is possible that the same occurs in canine CSM. Lower CSF PEDF in CSM-affected dogs might make them more vulnerable to SC glutamate excitotoxicity. Given the potent neuroprotective functions of PEDF, this molecule is being considered as a potential therapeutic agent in human neurodegenerative diseases 71 , 72 and might be useful in canine CSM. The PGH2 CSF concentration was also decreased in CSM-affected dogs. PGH2 (prostaglandin D synthetase or ß-trace protein) is a glycoprotein with high abundance in CSF, which is often altered in neurological disorders. [73] [74] [75] [76] [77] [78] [79] When there is blood-CSF barrier leakage, PGH2 CSF concentration decreases because of increased diffusion from CSF to serum. 73 , 74 The blood-SC barrier may be compromised in canine CSM causing leakage of PGH2 from CSF to serum and lower PGH2 CSF in CSM-affected dogs.
APOE and clusterin were downregulated in CSM-affected dogs but their expression increased secondary to corticosteroid use. In humans, the APOE4 isoform is associated with an elevated risk for several neurological disorders. 80 , 81 In human cervical spondylotic myelopathy, the APOE4 isoform increased the risk of developing clinical signs of myelopathy and was associated with a worse surgical outcome. 82 , 83 Given the involvement of APOE in human neurological disorders and the differential APOE expression between control and CSM-affected dogs, additional studies may be warranted to further investigate a possible role for this protein in the pathogenesis of canine CSM. Corticosteroid use can induce APOE expression, [84] [85] [86] consistent with the results of this study. Clusterin is a glycoprotein with various functions including an antiapoptotic role, involvement in neuronal survival, and complement inhibitory properties. 36 , 87-91 Neuronal and oligodendrocyte apoptosis occur in human cervical spondylotic myelopathy 92 and canine CSM, 93 and are implicated in disease progression. 3 The lower CSF clusterin concentrations identifi ed in CSM-affected dogs may compromise neuronal and oligodendrocyte survival by promoting apoptosis. Moreover, low clusterin may originate increased complement activation, which is supported by the results of this study because CSMaffected dogs had increased complement C3 CSF expression. Clusterin treatment accelerated recovery of nerve function in a rodent model of peripheral neuropathy and it represents a promising targeted therapy. 87 , 90 , 94 The use of corticosteroids increased the expression of clusterin in CSM-affected dogs, consistent with other studies. 94 Haptoglobin, transthyretin isoform 2, and cystatin C-like were upregulated in CSM-affected dogs in a corticosteroiddependent manner. Haptoglobin is an acute-phase protein, [95] [96] [97] and cystatin C is a proteinase inhibitor abundant in CSF. [98] [99] [100] In this study, these proteins were only upregulated in corticosteroid-treated CSM-affected dogs, which is consistent with a corticosteroid-related increase as described in other studies. [101] [102] [103] Transthyretin is a neuroprotective negative acute-phase protein and it is often downregulated in human neurological diseases. 26 , 96 Conversely, transthyretin was upregulated in CSM-affected dogs. This upregulation is likely secondary to corticosteroid use because both stress and corticosteroids can increase transthyretin expression in the choroid plexus. 104 Corticosteroid treatment can also decrease the CSF concentrations of multiple proteins. 105 , 106 Limitations of this study include the limited sample size and that several CSM-affected dogs were receiving corticosteroids at the time of CSF collection. This could have hindered the identifi cation of additional differentially expressed proteins but allowed us to identify proteins that were specifi cally altered by corticosteroid treatment in CSM-affected dogs. This study compared the CSF proteome of clinically normal and CSM-affected dogs. Many of the differentially expressed proteins are associated with damaged neural tissue, bone turnover, and/or compromised blood-SC barrier, which suggests the potential value of these proteins as biomarkers for canine CSM. The knowledge of the protein changes that occur in CSM and upon corticosteroid treatment of CSM-affected patients will aid in further understanding the pathomechanisms underlying this disease.
➢ Key Points
Eight proteins were signifi cantly upregulated in the CSF of CSM-aff ected dogs when compared with control dogs, including vitamin D-binding protein, gelsolin, creatine kinase B-type, angiotensinogen, α -2-HS-glycoprotein, SPARC, calsyntenin-1, and complement C3. The CSF of CSM-aff ected dogs demonstrated decreased expression of pigment epitheliumderived factor, prostaglandin-H2 D-isomerase, apolipoprotein E, and clusterin. In the CSF of CSM-aff ected dogs, corticosteroid treatment increased the expression of haptoglobin, transthyretin isoform 2, cystatin C-like, apolipoprotein E, and clusterin, and decreased the expression of angiotensinogen, α -2-HSglycoprotein, and gelsolin. This study provides an overview of diff erentially expressed proteins in the CSF of clinically normal and CSM-aff ected dogs and suggests the potential value of these proteins as biomarkers for canine CSM and their involvement in the disease pathogenesis.
